Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn A Phillips

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Medical Economics|June 2, 2020
Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS)Louis S Matza, Glenn A Phillips, Timothy A Howell, et al.
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
Patient Preference and Adherence|August 10, 2010
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophreniaDouglas L Noordsy, Glenn A Phillips, Daniel E Ball, et al.
Administration and Policy in Mental Health|April 8, 2009
Development of the burden of prior authorization of psychotherapeutics (BoPAP) scale to assess the effects of prior authorization among Texas Medicaid providersCarolyn M Brown, Esmond Nwokeji, Karen L Rascati, et al.
Muscle & Nerve|January 6, 2022
Utilization of MG-ADL in myasthenia gravis clinical research and careSrikanth Muppidi, Nicholas J Silvestri, Robin Tan, et al.
Journal of Medical Engineering & Technology|April 11, 2017
Validation of an ambient measurement system (AMS) for walking speedJonathan S Varsanik, Zebadiah M Kimmel, Carl de Moor, et al.
The Journal of Clinical Psychiatry|October 5, 2006
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidoneGlenn A Phillips, David L Van Brunt, Suraja M Roychowdhury, et al.
Journal of Affective Disorders|August 9, 2011
Development and validation of a patient-report measure of fatigue associated with depressionLouis S Matza, Glenn A Phillips, Dennis A Revicki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 18, 2014
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worseningGlenn A Phillips, Kathleen W Wyrwich, Shien Guo, et al.
Administration and Policy in Mental Health|December 8, 2007
Effects of a psychotherapeutic drug prior authorization (PA) requirement on patients and providers: a providers' perspectiveCarolyn M Brown, Kristin Richards, Karen L Rascati, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Medical Economics|June 2, 2020
Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS)Louis S Matza, Glenn A Phillips, Timothy A Howell, et al.
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
Patient Preference and Adherence|August 10, 2010
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophreniaDouglas L Noordsy, Glenn A Phillips, Daniel E Ball, et al.
Administration and Policy in Mental Health|April 8, 2009
Development of the burden of prior authorization of psychotherapeutics (BoPAP) scale to assess the effects of prior authorization among Texas Medicaid providersCarolyn M Brown, Esmond Nwokeji, Karen L Rascati, et al.
Muscle & Nerve|January 6, 2022
Utilization of MG-ADL in myasthenia gravis clinical research and careSrikanth Muppidi, Nicholas J Silvestri, Robin Tan, et al.
Journal of Medical Engineering & Technology|April 11, 2017
Validation of an ambient measurement system (AMS) for walking speedJonathan S Varsanik, Zebadiah M Kimmel, Carl de Moor, et al.
The Journal of Clinical Psychiatry|October 5, 2006
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidoneGlenn A Phillips, David L Van Brunt, Suraja M Roychowdhury, et al.
Journal of Affective Disorders|August 9, 2011
Development and validation of a patient-report measure of fatigue associated with depressionLouis S Matza, Glenn A Phillips, Dennis A Revicki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 18, 2014
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worseningGlenn A Phillips, Kathleen W Wyrwich, Shien Guo, et al.
Administration and Policy in Mental Health|December 8, 2007
Effects of a psychotherapeutic drug prior authorization (PA) requirement on patients and providers: a providers' perspectiveCarolyn M Brown, Kristin Richards, Karen L Rascati, et al.
Pageof 3